These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12116307)

  • 1. An increase in cost-effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing.
    Christiansen M; Olesen Larsen S
    Prenat Diagn; 2002 Jun; 22(6):482-6. PubMed ID: 12116307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome.
    Laigaard J; Spencer K; Christiansen M; Cowans NJ; Larsen SO; Pedersen BN; Wewer UM
    Prenat Diagn; 2006 Oct; 26(10):973-9. PubMed ID: 16892462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
    Dhaifalah I; Májek O
    Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women.
    Wøjdemann KR; Shalmi AC; Christiansen M; Larsen SO; Sundberg K; Brocks V; Bang J; Nørgaard-Pedersen B; Tabor A
    Ultrasound Obstet Gynecol; 2005 Mar; 25(3):227-33. PubMed ID: 15736185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical strategies in contingent sequential screening for Down syndrome.
    Benn P; Wright D; Cuckle H
    Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of first-trimester contingent screening strategies for Down syndrome.
    Sahota DS; Leung TY; Chan LW; Law LW; Fung TY; Chen M; Lau TK
    Ultrasound Obstet Gynecol; 2010 Mar; 35(3):286-91. PubMed ID: 20052660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first trimester 'combined test' for the detection of Down syndrome pregnancies in 4939 unselected pregnancies.
    Schuchter K; Hafner E; Stangl G; Metzenbauer M; Höfinger D; Philipp K
    Prenat Diagn; 2002 Mar; 22(3):211-5. PubMed ID: 11920896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada.
    Okun N; Teitelbaum M; Huang T; Dewa CS; Hoch JS
    Prenat Diagn; 2014 Apr; 34(4):350-6. PubMed ID: 24395030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
    Spencer K; Bindra R; Cacho AM; Nicolaides KH
    Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The best marker combination using the integrated screening test approach for detecting various chromosomal aneuploidies.
    Maymon R; Sharony R; Grinshpun-Cohen J; Itzhaky D; Herman A; Reish O
    J Perinat Med; 2005; 33(5):392-8. PubMed ID: 16238533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First- and second-trimester evaluation of risk for Down syndrome.
    Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
    Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.